Study of alteplase for respiratory failure in severe acute respiratory syndrome coronavirus 2/COVID‐19: Study design of the phase IIa STARS trial. Issue 6 (19th August 2020)

• Record Type: Journal Article
• Authors: Moore, Hunter B.; Barrett, Christopher D.; Moore, Ernest E.; Jhunjhunwala, Rashi; McIntyre, Robert C.; Moore, Peter K; Wang, Janice; Hajizadeh, Negin; Talmor, Daniel S.; Sauaia, Angela; Yaffe, Michael B.
• Is Part Of: Research and practice in thrombosis and haemostasis. Volume 4:Issue 6(2020)
• Page Start: 984
• Page End: 996
• Publication Date: 2020-08-19
• Subjects: acute respiratory distress syndrome -- clinical trial -- coagulopathy -- COVID‐19 -- fibrinolysis shutdown -- tissue‐type plasminogen activator; Thrombosis -- Periodicals; Hemostasis -- Periodicals; 616.135005
• DOI: 10.1002/rth2.12395
• Languages: English
• ISSNs: 2475-0379

Abstract

Abstract: Background: The coronavirus disease 2019 (COVID‐19) pandemic has caused a large surge of acute respiratory distress syndrome (ARDS). Prior phase I trials (non–COVID‐19) demonstrated improvement in pulmonary function in patients ARDS using fibrinolytic therapy. A follow‐up trial using the widely available tissue‐type plasminogen activator (t‐PA) alteplase is now needed to assess optimal dosing and safety in this critically ill patient population. Objective: To describe the design and rationale of a phase IIa trial to evaluate the safety and efficacy of alteplase treatment for moderate/severe COVID‐19–induced ARDS. Patients/Methods: A rapidly adaptive, pragmatic, open‐label, randomized, controlled, phase IIa clinical trial will be conducted with 3 groups: intravenous alteplase 50 mg, intravenous alteplase 100 mg, and control (standard‐of‐care). Inclusion criteria are known/suspected COVID‐19 infection with PaO2 /FiO2 ratio <150 mm Hg for > 4 hours despite maximal mechanical ventilation management. Alteplase will be delivered through an initial bolus of 50 mg or 100 mg followed by heparin infusion for systemic anticoagulation, with alteplase redosing if there is a >20% PaO2 /FiO2 improvement not sustained by 24 hours. Results: The primary outcome is improvement in PaO2 /FiO2 at 48 hours after randomization. Other outcomes include ventilator‐ and intensive care unit–free days, successful extubation (no reintubation ≤3 days after initial extubation), and mortality. Fifty eligible patients will be enrolled in a rapidly adaptive, modified stepped‐wedge design with 4 looks at the data. Conclusion: Findings will provide timely information on the safety, efficacy, and optimal dosing of t‐PA to treat moderate/severe COVID‐19–induced ARDS, which can be rapidly adapted to a phase III trial (NCT04357730; FDA IND 149634).